Introduction
Repeated-dose oral toxicity testing, as outlined in OECD Test Guideline 408, evaluates the adverse effects of a test substance when administered orally over an extended period, typically 90 days. This subchronic study is critical for identifying target organ toxicity, establishing no observed adverse effect levels (NOAELs), and determining dose-response relationships. It is an essential component of safety assessments required for Investigational New Drug (IND) applications, as well as for agrochemicals, industrial compounds, food additives, and consumer products.
The OECD 408 study helps predict the potential human health risks associated with prolonged exposure to a substance and supports the establishment of safe exposure limits. The data generated from this study are used in regulatory submissions to agencies such as the FDA, EMA, EPA, and international chemical safety authorities.
Study Objective and Regulatory Purpose
The primary objective of the OECD 408 study is to detect toxic effects that may not be evident during shorter-duration studies. It provides insight into cumulative toxicity, delayed onset effects, and the potential for recovery after exposure ends. This study is considered a benchmark for identifying dose levels suitable for chronic toxicity testing, carcinogenicity studies, and reproductive and developmental toxicity evaluations.
In the context of pharmaceutical development, repeated-dose oral toxicity data are required before initiating Phase I clinical trials, especially when the oral route is intended for human administration. It also informs the design of longer-term studies by helping to establish maximum tolerated doses and identifying dose-limiting toxicities.
Study Design and Methodology
The OECD 408 study is conducted in rodents, typically rats, with three dose groups and a concurrent control group. Each group usually includes ten animals per sex. The test substance is administered daily by oral gavage for 90 consecutive days. The study may also include a satellite recovery group that is observed for an additional 28-day post-treatment period to assess reversibility or persistence of any toxic effects.
Throughout the study, animals are monitored for clinical signs of toxicity, changes in body weight, food and water consumption, and behavior. Hematological and clinical chemistry analyses are conducted at designated intervals to detect systemic effects. At study termination, a comprehensive necropsy is performed, including organ weight measurements and histopathological examination of a wide range of tissues.
Parameters assessed include effects on the liver, kidneys, hematopoietic system, gastrointestinal tract, endocrine function, and central nervous system. Standard toxicokinetic assessments may also be incorporated, especially in support of drug development programs.
Toxicological Endpoints and Interpretation
Key endpoints include clinical pathology (blood and serum chemistry), gross necropsy findings, organ weight changes, and microscopic lesions. Adverse findings are evaluated in the context of dose response, sex differences, and temporal progression. The identification of a NOAEL is a critical outcome, used for calculating human safety margins and determining safe starting doses in clinical trials.
In some cases, additional evaluations such as hormone analysis, sperm parameters, or immune profiling may be included depending on the nature of the test substance and its suspected mechanism of action.
Applications in IND-Enabling Toxicology
The OECD 408 study is a cornerstone of IND-enabling toxicology for orally administered therapeutics. It provides the nonclinical data necessary to support first-in-human dosing by characterizing the safety profile of the compound over an extended period. This information is essential for establishing clinical monitoring parameters and informing risk mitigation strategies.
In chemical risk assessment, the results are used to define occupational exposure limits, establish acceptable daily intakes, and support hazard classification. The findings from OECD 408 studies are also instrumental in environmental and consumer safety evaluations for substances found in food, water, packaging, and consumer products.
Altogen Labs Repeated-Dose Toxicology Services
Altogen Labs offers GLP-compliant repeated-dose oral toxicity studies following OECD 408 guidelines. Our state-of-the-art facility and experienced scientific team ensure the highest quality in study execution, data analysis, and reporting. Study designs are tailored to each compound’s characteristics and intended use, with customizable endpoints and flexible scheduling to meet program timelines.
Altogen Labs supports pharmaceutical sponsors, biotechnology firms, and industrial chemical manufacturers with full-service IND toxicology capabilities. Our services include study planning, protocol development, dose formulation, clinical pathology, histopathology, and submission-ready reporting. Each study is conducted with strict adherence to regulatory requirements to ensure global acceptance of the data.